Home > Research > Publications & Outputs > A body image scale for use with cancer patients
View graph of relations

A body image scale for use with cancer patients

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

A body image scale for use with cancer patients. / Hopwood, P; Fletcher, Ian; Lee, A et al.

In: European Journal of Cancer, Vol. 37, No. 2, 2001, p. 189-197.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Hopwood, P, Fletcher, I, Lee, A & Al Ghazal, S 2001, 'A body image scale for use with cancer patients', European Journal of Cancer, vol. 37, no. 2, pp. 189-197. https://doi.org/10.1016/S0959-8049(00)00353-1

APA

Hopwood, P., Fletcher, I., Lee, A., & Al Ghazal, S. (2001). A body image scale for use with cancer patients. European Journal of Cancer, 37(2), 189-197. https://doi.org/10.1016/S0959-8049(00)00353-1

Vancouver

Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. European Journal of Cancer. 2001;37(2):189-197. doi: 10.1016/S0959-8049(00)00353-1

Author

Hopwood, P ; Fletcher, Ian ; Lee, A et al. / A body image scale for use with cancer patients. In: European Journal of Cancer. 2001 ; Vol. 37, No. 2. pp. 189-197.

Bibtex

@article{82b9c29452534548945cebb6f13f2a9f,
title = "A body image scale for use with cancer patients",
abstract = "Body image is an important endpoint in quality of life evaluation since cancer treatment may result in major changes to patients' appearance from disfiguring surgery, late effects of radiotherapy or adverse effects of systemic treatment. A need was identified to develop a short body image scale (BIS) for use in clinical trials. A 10-item scale was constructed in collaboration with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Study Group and tested in a heterogeneous sample of 276 British cancer patients. Following revisions, the scale underwent psychometric testing in 682 patients with breast cancer, using datasets from seven UK treatment trials/clinical studies. The scale showed high reliability (Cronbach's alpha 0.93) and good clinical validity based on response prevalence, discriminant validity (P<0.0001, Mann–Whitney test), sensitivity to change (P<0.001, Wilcoxon signed ranks test) and consistency of scores from different breast cancer treatment centres. Factor analysis resulted in a single factor solution in three out of four analyses, accounting for >50% variance. These results support the clinical validity of the BIS as a brief questionnaire for assessing body image changes in patients with cancer, suitable for use in clinical trials.",
keywords = "Assessment, Body image, Cancer, Clinical trials, Questionnaire",
author = "P Hopwood and Ian Fletcher and A Lee and {Al Ghazal}, S",
year = "2001",
doi = "10.1016/S0959-8049(00)00353-1",
language = "English",
volume = "37",
pages = "189--197",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "2",

}

RIS

TY - JOUR

T1 - A body image scale for use with cancer patients

AU - Hopwood, P

AU - Fletcher, Ian

AU - Lee, A

AU - Al Ghazal, S

PY - 2001

Y1 - 2001

N2 - Body image is an important endpoint in quality of life evaluation since cancer treatment may result in major changes to patients' appearance from disfiguring surgery, late effects of radiotherapy or adverse effects of systemic treatment. A need was identified to develop a short body image scale (BIS) for use in clinical trials. A 10-item scale was constructed in collaboration with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Study Group and tested in a heterogeneous sample of 276 British cancer patients. Following revisions, the scale underwent psychometric testing in 682 patients with breast cancer, using datasets from seven UK treatment trials/clinical studies. The scale showed high reliability (Cronbach's alpha 0.93) and good clinical validity based on response prevalence, discriminant validity (P<0.0001, Mann–Whitney test), sensitivity to change (P<0.001, Wilcoxon signed ranks test) and consistency of scores from different breast cancer treatment centres. Factor analysis resulted in a single factor solution in three out of four analyses, accounting for >50% variance. These results support the clinical validity of the BIS as a brief questionnaire for assessing body image changes in patients with cancer, suitable for use in clinical trials.

AB - Body image is an important endpoint in quality of life evaluation since cancer treatment may result in major changes to patients' appearance from disfiguring surgery, late effects of radiotherapy or adverse effects of systemic treatment. A need was identified to develop a short body image scale (BIS) for use in clinical trials. A 10-item scale was constructed in collaboration with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Study Group and tested in a heterogeneous sample of 276 British cancer patients. Following revisions, the scale underwent psychometric testing in 682 patients with breast cancer, using datasets from seven UK treatment trials/clinical studies. The scale showed high reliability (Cronbach's alpha 0.93) and good clinical validity based on response prevalence, discriminant validity (P<0.0001, Mann–Whitney test), sensitivity to change (P<0.001, Wilcoxon signed ranks test) and consistency of scores from different breast cancer treatment centres. Factor analysis resulted in a single factor solution in three out of four analyses, accounting for >50% variance. These results support the clinical validity of the BIS as a brief questionnaire for assessing body image changes in patients with cancer, suitable for use in clinical trials.

KW - Assessment

KW - Body image

KW - Cancer

KW - Clinical trials

KW - Questionnaire

U2 - 10.1016/S0959-8049(00)00353-1

DO - 10.1016/S0959-8049(00)00353-1

M3 - Journal article

VL - 37

SP - 189

EP - 197

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 2

ER -